P.065 Comparison in outcomes by sex in acute ischemic stroke patients treated with alteplase versus tenecteplase: a subgroup analysis of AcT

Background: Sex differences in treatment response to intravenous thrombolysis (IVT) are poorly characterized. We compared sex-disaggregated outcomes patients receiving IVT for acute ischemic stroke the Alteplase Tenecteplase (AcT) trial, a Canadian multicentre, randomised trial. Methods: In this post-hoc analysis, primary outcome was excellent functional (modified Rankin Score [mRS] 0-1) at 90 days. Secondary and safety included return baseline function, successful reperfusion (eTICI≥2b), death symptomatic intracerebral hemorrhage. Results: Of 1577 patients, there were 755 women 822 men (median age 77 [68-86]; 70 [59-79]). There no rates of mRS 0-1 (aRR 0.95 [0.86-1.06]), function 0.94 [0.84-1.06]), 0.98 [0.80-1.19]) 0.91 [0.79-1.18]). effect modification by type on association between sex outcomes. The probability decreased with increasing onset-to-needle time. This relation did not vary (p interaction 0.42). Conclusions: AcT trial demonstrated comparable functional, angiographic sex. differ alteplase tenecteplase. pragmatic enrolment broad national participation provide reassurance that do appear be amongst Canadians IVT.